Acquired type 2A von Willebrand's syndrome as concomitant effect of a dialysis shunt;Erworbenes von-willebrand-syndrom Typ 2A als begleit-erscheinung eines dialyseshunts?

Hamostaseologie

Volumn 31, Issue 2, 2011, Pages 118-122

  Leimkuhler K ^a   Bach, F ^a   Kuhlmann, S ^a   Feidicker, B ^a   Heim, M U ^b   Susemihl, C ^a   Schmidt, B ^a   Mertzlufft, F ^a  

^a EVANGELISCHES KRANKENHAUS   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Acquired von Willebrand's disease; Arteriovenous fistula; Bleeding; Shear stress

Indexed keywords

AUTOANTIBODY; HETASTARCH; VON WILLEBRAND FACTOR;

ACQUIRED VON WILLEBRAND DISEASE; ADULT; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING DISORDER; CASE REPORT; DISEASE DURATION; FEMALE; HUMAN; RENAL REPLACEMENT THERAPY; SHEAR STRESS; VON WILLEBRAND DISEASE; ARTERIOVENOUS SHUNT; BLEEDING; BLOOD; BLOOD CLOTTING TEST; FOLLOW UP; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATION; RISK FACTOR;

ADULT; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD COAGULATION TESTS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RENAL DIALYSIS; RISK FACTORS; VON WILLEBRAND DISEASE, TYPE 2;

EID: 80051953692     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1129     Document Type: Article

References (33)

1. Allon M. Current management of vascular access. Clin J Am Soc Nephrol 2007; 2: 786-800.
2. Bowen DJ, Collins PW. Insights into von Willebrand factor proteolysis: clinical implications. Br J Haematol 2006; 133: 457-467.
3. Brescia MJ, Cimino JE, Appel K et al. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N Engl J Med 1966; 275: 1089-1092.
4. Brittinger WD, Twittenhoff WD. Anschlussverfahren an die künstliche Niere. Stuttgart: Thieme 2005; 8.
5. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-311.
6. Casonato A, Pontara E, Doria A et al. Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome. Br J Haematol 2002; 116: 899-904.
7. Cattaneo M, Federici AB, Lecchi A et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 35-39.
8. Cuker A, Connors JM, Katz JT et al. Bloody mystery. N Engl J Med 2009; 361: 1887-1894.
9. Favaloro EJ, Grispo L, Exner T et al. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2: 285-291.
10. Federici AB, Rand JH, Bucciarelli P et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345-349, 739.
11. Federici AB. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 2006; 43: (Suppl 1): S48-S58.
12. Heilmann C, Geisen U, Beyersdorf F et al. Acquired von Willebrand syndrome in patients with ventricular assist device or total artificial heart. Thromb Haemost 2010; 103: 962-967.
13. Hepp W, Koch M, Konner K. Dialyseshunts. Grundlagen, Chirurgie, Komplikationen. Darmstadt: Steinkopff 2009: 119-134.
14. Huijbregts HJT, Bots ML, Wittens CHA et al. on behalf of the CIMINO study group. Hemodialysis Arteriovenous Fistula Patency Revisited: Results of a Prospective, Multicenter Initiative. Clin J Am Soc Nephrol 2008; 3: 714-719.
15. Jonville-Béra AP, Autret-Leca E, Gruet Y. Acquired type I von Willebrand's disease associated with highly substituted hydroxyethyl starch. N Engl J Med 2001; 345: 622-623.
16. Macfarlane DE, Stibbe J, Kirby EP et al. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308.
17. Manucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-694.
18. Mohri H. Acquired von Willebrand syndrome: features and management. Am J Hematol 2006; 81: 616-623.
19. Nishino M, Girma JP, Rothschild C et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-1599.
20. Reininger AJ, Angerer J, Napoleone M et al. High shear dependent, reversible VWF network assembly and concomitant reversible platelet aggregation. Hämostaseologie 2010; 30: A8.
21. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-1143.
22. Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-1325.
23. Sadler JE. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003; 349: 323-325.
24. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
25. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-525.
26. Schneppenheim R, Budde U. Angeborenes und erworbenes von-Willebrand-Syndrom. Hämostaseologie 2008; 28: 312-319.
27. Siediecki CA, Lestini BJ, Kottke-Marchant KK et al. Shear-dependent changes in the threedimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
28. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83: 2171-2179.
29. Turner NA, Nolasco L, Ruggeri ZM et al. Endothelial cell ADAMTS-13 and VWF: Production, release, and VWF string cleavage. Blood 2009; 114: 5102-5111.
30. Van Haren B, Wouters N, Brouwer M et al. Correction of von Willebrand factor multimer abnormalities in severe aortic valve stenosis after percutaneous aortic valve replacement. Hämostaseologie 2010; 30: A67.
31. Vincentelli A, Susen S, Le Tourneau T et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-349.
32. Weiss HJ, Hoyer LW, Rickles FR et al. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation: relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973; 52: 2708-2716.
33. Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 1971; 50: 244-254.